Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (NASDAQ: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA…

Click here to view original post